INMInMed Pharmaceuticals Inc.
Health Care
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest revised down 6.5% for FY 2025
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2025
Notable restatement-$8.7M▼ 6.5%
was-$8.2M
Revised down in a S-4/A.
Amended filing
As reported · Sep 23, 2025S-4/A · Sep 30, 2026us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestVerify against SEC filingsShow
As reported-$8.2M
Accepted 2025-09-230001213900-25-090210
Restated-$8.7M
Accepted 2026-09-300001193125-26-407792
PretaxIncome · reported 5 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get a signal the next time INM — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.